Cryoport, Inc.

CYRX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001124524

C/D

on the C/D boundary of 369 graded peers in healthcare

rank 223 of 369; percentile 60.3; sampling error 2.5 points; lower is stronger

A B C D E

C/D, the tortoise



Scoreboard

Profitability	D	percentile 62.9
Solvency	B	percentile 37.2
Growth and financing	C	percentile 55.3
Reliability	0.91 AUC	filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets	total assets $765.0M
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	late filer	
Inputs computable	9 of 14	
Graded from	filings received through Mar 5, 2026	250 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$20.46	2026-11-09; market equity $1.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy ("CGT") market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 62.9						
Gross profitability	10.9%	32.3%		75.3	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

a prior annual debt, equity, and cash observation is required					
Accruals ratio	11.8%	(6.6%)	92.4	800	2025-12-31
Gross margin stability, five years	1.3 pts	2.8 pts	21.2	242	2025-12-31
Solvency, sleeve percentile 37.2					
Twelve-month failure probability	0.02%	0.08%	9.7	248	2026-09-30
Altman Z double-prime	0.96	(0.35)	32.8	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.17x	2.95x	69.0	826	2025-12-31
Growth and financing, sleeve percentile 55.3					
Revenue growth, three-year compound	(9.4%)	10.1%	85.1	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(9.7%)	2.2%	69.4	694	2025-12-31
Net share issuance, one year	(0.1%)	2.5%	11.3	629	2026-02-27

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
218	Mannkind Corp. (MNKD)	59.0	C/D	
219	Tango Therapeutics, Inc. (TNGX)	59.2	C/D	dilution
220	Trulieve Cannabis Corp. (TRLV)	59.5	C/D	fortress balance sheet
221	Labcorp Holdings Inc. (LH)	59.8	C/D	
222	Twist Bioscience Corp. (TWST)	60.1	C/D	fortress balance sheet
223	Cryoport, Inc. (CYRX)	60.3	C/D	late filer
224	Amylyx Pharmaceuticals, Inc. (AMLX)	60.6	C/D	degenerate inputs
225	ARS Pharmaceuticals, Inc. (SPRY)	60.9	C/D	short runway, distress
226	Teva Pharmaceutical Industries Ltd. (TEVA)	61.1	C/D	
227	Akebia Therapeutics, Inc. (AKBA)	61.4	C/D	fortress balance sheet
228	Embecta Corp. (EMBC)	61.7	C/D	late filer

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	88.3%	(1.9%)	87
Distance from 52-week high	0.0%	(27.5%)	90
EBIT to enterprise value	(4.8%)	(1.5%)	42
Free cash flow yield	(2.4%)	(1.0%)	46
Book value to price	0.47	0.27	66
Sales to price	0.17	0.29	36
Composite equity issuance, five years	10.6%	20.8%	40
Relative strength against the sector, log excess return	0.47	(0.19)	87

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$279.2M
Operating cash flow, four quarters	$11.0M
Months of runway	not finite
Days since last periodic filing	5 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$10.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$83.1M	2025-12-31	2026-03-05	10-K	26-024180
2	assets	us-gaap:Assets	$765.0M	2025-12-31	2026-03-05	10-K	26-024180
3	operating income	us-gaap:OperatingIncomeLoss	-$6.3M	2013-03-31	2014-06-25	10-K	14-039508
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$6.4M	2013-03-31	2014-06-25	10-K	14-039508
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$1,600	2013-03-31	2014-06-25	10-K	14-039508
6	total debt	us-gaap:LongTermDebt	$1.3M	2013-03-31	2013-06-25	10-K	13-036463
7	book equity	us-gaap:StockholdersEquity	-$2.1M	2013-03-31	2015-05-19	10-K	15-032332
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$563,104	2013-03-31	2015-05-19	10-K	15-032332
9	net income	us-gaap:NetIncomeLoss	$78.3M	2025-12-31	2026-03-05	10-K	26-024180
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.6M	2025-12-31	2026-03-05	10-K	26-024180
11	assets	us-gaap:Assets	$703.5M	2024-12-31	2026-03-05	10-K	26-024180
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$176.2M	2025-12-31	2026-03-05	10-K	26-024180
13	gross profit	us-gaap:GrossProfit	$69.7M	2024-12-31	2026-03-05	10-K	26-024180
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$156.8M	2024-12-31	2026-03-05	10-K	26-024180
15	gross profit	us-gaap:GrossProfit	$75.3M	2023-12-31	2026-03-05	10-K	26-024180
16	revenue	us-gaap:Revenues	$168.7M	2023-12-31	2026-03-05	10-K	26-024180
17	gross profit	us-gaap:GrossProfit	$103.9M	2022-12-31	2025-03-07	10-K	25-002509
18	revenue	us-gaap:Revenues	$237.3M	2022-12-31	2025-03-07	10-K	25-002509

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	gross profit	us-gaap:GrossProfit	$96.6M	2021-12-31	2024-03-13	10-K	24-003128
20	revenue	us-gaap:Revenues	$222.6M	2021-12-31	2024-03-13	10-K	24-003128
21	current assets	us-gaap:AssetsCurrent	$476.2M	2025-12-31	2026-03-05	10-K	26-024180
22	current liabilities	us-gaap:LiabilitiesCurrent	$219.0M	2025-12-31	2026-03-05	10-K	26-024180
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$688.9M	2025-12-31	2026-03-05	10-K	26-024180
24	operating income	us-gaap:OperatingIncomeLoss	-$36.8M	2025-12-31	2026-03-05	10-K	26-024180
25	book equity	us-gaap:StockholdersEquity	$502.6M	2025-12-31	2026-03-05	10-K	26-024180
26	liabilities	us-gaap:Liabilities	$262.4M	2025-12-31	2026-03-05	10-K	26-024180
27	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$393,959	2013-03-31	2014-06-25	10-K	14-039508
28	operating income	us-gaap:OperatingIncomeLoss	-$100.5M	2023-12-31	2026-03-05	10-K	26-024180
29	interest expense	us-gaap:InterestExpense	$5.5M	2023-12-31	2024-03-13	10-K	24-003128
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$16.4M	2025-12-31	2026-03-05	10-K	26-024180
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$16.3M	2024-12-31	2026-03-05	10-K	26-024180
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$17.3M	2024-12-31	2026-03-05	10-K	26-024180
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$757,000	2023-12-31	2026-03-05	10-K	26-024180
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$38.8M	2023-12-31	2026-03-05	10-K	26-024180
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$1.9M	2022-12-31	2025-03-07	10-K	25-002509
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$22.1M	2022-12-31	2025-03-07	10-K	25-002509
37	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$27.7M	2025-12-31	2026-03-05	10-K	26-024180
38	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$32.2M	2025-12-31	2026-03-05	10-K	26-024180
39	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.8M	2025-12-31	2026-03-05	10-K	26-024180
40	current assets	us-gaap:AssetsCurrent	$341.6M	2024-12-31	2026-03-05	10-K	26-024180
41	current liabilities	us-gaap:LiabilitiesCurrent	$64.6M	2024-12-31	2026-03-05	10-K	26-024180
42	assets	us-gaap:Assets	$957.7M	2023-12-31	2025-03-07	10-K	25-002509
43	assets	us-gaap:Assets	$1.0B	2022-12-31	2024-03-13	10-K	24-003128
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,856,135	2026-02-27	2026-03-05	10-K	26-024180
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,910,391	2025-02-28	2025-03-07	10-K	25-002509

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.